National Cancer Institute - NCI Division of Cancer Treatment and ...

Not only does CTEP identify promising agents for evaluation,
but also it identifies biomolecular characteristics of malignant
tumors that investigators may be able to exploit clinically.
66 ■ P R O G R A M A C C O M P L I S H M E N T S 2 0 0 6
■ ■ ■
CTEP houses NCI’s primary program
for evaluating new anticancer
treatments. It also provides and
tracks experimental agents for clinical
trials run by other NCI components.
During fiscal year 2005, CTEP:
■ Managed 942 active clinical trials
■ Supervised 127 active Investigational
New Drugs (INDs)
■ Oversaw the recruitment of
nearly 31,000 patients to CTEPsponsored
clinical trials
tumors that investigators may be able to
exploit clinically. CTEP accomplishes its
goals by administering, coordinating, and
funding clinical trials, as well as sponsoring
other clinical research. The program fosters
collaborations within the cancer research
community and works extensively with
the pharmaceutical and biotechnology
industries. CTEP also reaches out to
patients and advocates to help establish
research priorities. The program administered
399 grants in 2005 and played a role
in 942 open clinical trials.
NCI Visuals Online.